Advances in the management of esophageal cancer by MINSKY, Bruce D.
Marmara Medical Journal 2015; 28 (Special issue 1): 3-10
DOI:10.5472/mmj.10059
   REVIEW ARTICLE
3
Advances in the management of esophageal cancer
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ABSTRACT
The management of clinical stage III and IVa esophageal 
cancer has evolved in the past 2 decades. Based on the Cross 
trial, neoadjuvant chemoradiation, followed by surgical 
resection has become standard. For medically inoperable, 
definitive chemoradiation is most commonly used. The 
standard radiation dose is 50.4 Gy although trials of dose-
escalation are ongoing. At the current time, there are no 
definitive biomarkers to predict response. 
Keywords: Esophageal cancer, Radiation therapy, 
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NONOPERATIVE THERAPY
Radiation therapy alone
Radiation therapy alone is limited to palliation or for 
patients who are medically unable to tolerate chemotherapy. 
The 5-year survival rate for patients treated with conventional 
doses of radiation therapy alone is 0-10% [1-3]. In the radiation 
therapy alone arm of the RTOG 85-01 trial in which patients 
received 64 Gy at 2 Gy/day with conventional techniques, all 
patients were all dead of disease by 3 years [4,5]. Shi and 
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colleagues reported a 33% 5-year survival rate with the use 
of late course accelerated fractionation to a total dose of 68.4 
Gy [6-12].
Dose intensification with brachytherapy
Brachytherapy can be delivered by low or high dose rates 
and has previously been used as a boost following external 
beam radiation therapy or chemoradiation [7-16]. This 
technique is limited by the effective treatment distance. 
The primary isotope is 192Ir, which is usually prescribed 
to treat to a distance of 1 cm from the source. Therefore, as 
confirmed by pathologic analysis of treated specimens, any 
portion of the tumor which is >1 cm from the source will 
receive a suboptimal radiation dose [17].
Retrospective and single institution trials suggest that 
there is no advantage of adding brachytherapy to external 
beam radiation. Chemoradiation plus brachytherapy was 
tested prospectively by the RTOG 92-07 trial. A total of 
75 patients with cancers of the thoracic esophagus (92% 
squamous cell, 8% adenocarcinoma) received the RTOG 
85-01 50 Gy chemoradiation regimen followed by a boost 
during cycle 3 of chemotherapy with either low dose rate 
or high dose rate intraluminal brachytherapy [22]. Due 
to low accrual the low dose rate option was discontinued 
and the analysis was limited to patients who received the 
high dose rate treatment. High dose rate brachytherapy was 
delivered in weekly fractions of 5 Gy during weeks 8, 9, 
and 10. Several patients developed fistulas and the fraction 
delivered at week 10 was discontinued. The complete 
response rate was 73%. With a median follow-up of only 
11 months, local failure as the first site of failure was 27%. 
Acute toxicities were high. These included 58% grade 3, 
26% grade 4, and 8% grade 5 (treatment-related death). The 
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cumulative incidence of fistula was 18%/year and the crude 
incidence was 14%. Of the 6 treatment related fistulas, 3 
were fatal. Given the significant toxicity and lack of efficacy 
there is limited interest in this technique. 
However, if brachytherapy is to be used, guidelines 
for esophageal brachytherapy have been published by the 
American Brachytherapy Society are available [23]. For 
patients treated in the curative setting brachytherapy should 
be limited to tumors ≤ 10 cm with no evidence of distant 
metastasis. Contraindications include tracheal or bronchial 
involvement, cervical esophagus location, or stenosis which 
cannot be bypassed. The applicator should have an external 
diameter of 6-10 cm. If chemoradiation is used (defined as 
5-FU based chemotherapy plus 45-50 Gy) the recommended 
doses of brachytherapy are 10 Gy in 2 weekly fractions of 5 
Gy each for high dose rate and 20 Gy in a single fraction at 
4-10 Gy/hr for low dose rate. The doses should be prescribed 
to 1 cm from the source. Lastly, brachytherapy should be 
delivered after the completion of external beam and not 
concurrently with chemotherapy. 
Primary chemoradiation
Although there are 6 randomized trials comparing definitive 
radiation therapy alone with chemoradiation, the only 
trial which designed to deliver adequate doses of systemic 
chemotherapy with concurrent radiation therapy was the 
RTOG 85-01 trial reported by Herskovic and colleagues [23-
26]. As was common in the 1980s, most patients had SCC. 
Treatment included four cycles of 5-FU (1000 mg/m2/24 
hr x 4 days) and Cisplatin (75 mg/m2, day 1). Radiation 
therapy (50 Gy at 2 Gy/day) was given concurrently with 
the first day of cycle 1 of chemotherapy. Cycles 3 and 4 
of chemotherapy were delivered every 3 weeks rather than 
every 4 weeks. Only 50% of the patients finished all 4 cycles 
of the chemotherapy. The control arm was radiation therapy 
alone, albeit a higher dose (64 Gy) than the chemoradiation 
arm. 
Patients treated with chemoradiation had a significant 
improvement in both median (14 months vs. 9 months), 
and 5 year survival (27% vs. 0%, p< 0.0001) [25]. The 8 
year survival was 22% [26]. Histology did not significantly 
influence the results. The 5-year survival was 21% for 
the 107 patients with SCC vs. 13% of the 23 patients 
with adenocarcinoma, (p=NS). Local failure (defined as 
local persistence plus recurrence) was also lower in the 
chemoradiation arm (47% vs. 65%). Although African 
Americans had larger primary tumors of which all were 
SCC, there was no difference in survival compared with 
Caucasians [27].
Dose intensification with external beam escalation
This concept was prospectively examined in INT 0123 
(RTOG 9405) [29]. In this trial, patients selected for a non-
surgical approach were randomized to a slightly modified 
RTOG 85-01 chemoradiation regimen with 50.4 Gy versus 
the same chemotherapy with 64.8 Gy, based on INT 0122. 
As with RTOG 85-01, the majority of patients (85%) had 
SCC. The trial opened in late 1994 and was closed in 1999 
when an interim analysis revealed that it was unlikely 
that the high dose arm would achieve a superior survival 
compared to the standard dose arm. 
For the 218 eligible patients, there was no significant 
difference in median survival (13.0 months vs. 18.1 months), 
2-year survival (31% vs. 40%), or local/regional failure 
and/or local/regional persistence of disease (56% vs. 52%) 
between the high dose and standard dose arms. Although 
11 treatment-related deaths occurred in the high dose arm 
compared with two in the standard dose arm, seven of the 11 
occurred in patients who had received ≤ 50.4 Gy. 
An alternative approach to dose escalation is altered 
fractionation. This has revealed mixed results. Zaho 
and colleagues treated 201 patients with squamous cell 
cancer using 41.4 Gy followed by late-course accelerated 
hyperfractionation to 68.4 Gy [30]. The results were similar 
to RTOG 85-01 (38% local failure and 26% 5-year survival). 
Choi and colleagues treated 46 patients with 5-FU/cisplatin 
and BID radiation using a concurrent boost technique and 
reported a 37% 5-year survival [31]. Additionally, Lee et 
al reported on a trial of 102 patients with LAEC, limited 
to SCC, randomized to surgery alone versus preoperative 
therapy with 45.6 Gy (1.2 Gy BID) plus 5-FU/cisplatin 
[32]. There was no difference in median survival (28 vs. 27 
months). Thus, although these approaches may appear to be 
reasonable, there appears to be a significant increase in acute 
toxicity without any clear therapeutic benefit. 
The above trials used 2D and 3D techniques. Newer 
techniques such as IMRT and protons may be able to deliver 
higher doses of radiation with a more tolerable toxicity profile. 
Multiple dosimetric studies comparing standard 3D-conformal 
radiotherapy and IMRT, generally have found improved 
sparing of the heart, lung or both using either static field or 
arc-based IMRT [33-44]. Retrospective data do not suggest 
inferior outcome and may provide decreased toxicity vs. non-
IMRT treatment techniques [45-47]. Investigators at the MD 
Anderson reported the results of 676 patients treated with either 
IMRT (263) or 3DCRT (413) [45]. On multivariate analysis, 
IMRT was associated with improved survival (p=0.004), but 
not cancer specific survival (p=0.86). The survival difference 
between 3DCRT and IMRT was thought to be due to a higher 
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level of cardiac (p=0.05) and unexplained deaths (p= 0.003) in 
the 3DCRT patients, suggesting that decreased cardiac dose 
may have a direct impact on patient outcome. A randomized 
trial is unlikely, therefore the available data may represent the 
best comparison.  
Another theoretical advantage of IMRT is the possibility 
of dose escalation. With the use of IMRT, a simultaneous 
integrated boost (SIB) may be performed while maintaining 
commonly used lung and heart dosimetric constraints. 
Retrospective data from Zhang and colleagues suggest a 
positive correlation between radiation dose and locoregional 
control [48]. 
Neoadjuvant chemotherapy
A potential advantage of neoadjuvant chemotherapy is the 
early identification of those patients who may or may not 
respond to the chemotherapeutic regimen being delivered 
concurrently with chemoradiation. Data from Ilson et al 
suggest that the change in SUV on FDG-PET scan was able 
to predict which patients showed a response to chemotherapy 
[49]. Weider and associates reported similar findings in 38 
patients with squamous cell cancers [50]. Although this 
approach is investigational, if the non-responders can be 
identified early, changing the chemotherapeutic regimen 
may be helpful. However, in the context of induction 
chemotherapy prior to definitive chemoradiation, the data 
do not support its routine use. For example, Ruhstaller 
and colleagues report the outcomes from a phase II trial 
using cisplatin/docetaxel followed by chemoradiation 
[51]. The median survival was 16 months, with 29% of 
patients surviving long term suggesting no benefit over 
chemoradiation alone. 
NEOADJUVANT THERAPY
Preoperative chemoradiation
There are seven randomized trials comparing preoperative 
combined modality therapy with surgery alone in patients 
with clinically resectable disease, the most recent being the 
CROSS trial [32, 55-60].
The CROSS trial randomized 366 patients (75% 
adenocarcinoma, 23% squamous cell) to receive either 
neoadjuvant chemoradiation with 41.4 Gy and carboplatin/
paclitaxel followed by surgical resection versus surgical 
resection alone [60]. In median survival was 49.4 vs. 24 
months, p=0.003, respectively. Improved survival was seen 
in both adenocarcinoma and SCC, although the magnitude 
was slightly greater in squamous cell. The R0 resection 
was 93% in the chemoradiation arm, compared to 69% 
in the surgery alone arm (p<0.001) and the pCR rate was 
29%. There was no significant difference in perioperative 
complications was seen between treatment arms. 
Prior to the publication of the CROSS trial the role of 
preoperative chemoradiation was controversial. The first 6 
trials (Urba [55], Walsh [56], EORTC [57], Australasian 
[58], Korea [32], and CALGB 9781 [59]) had limited 
patient numbers, heterogeneous treatment regimens, and 
in some the dose of radiation was insufficient based. With 
the publication of the CROSS trial the standard of care for 
patients with locally advanced but medically resectable 
adenocarcinoma of the esophagus is now preoperative 
chemoradiation. 
Is surgery necessary following chemoradiation?
Given the response rate to chemoradiation and the morbidity 
of surgery, two randomized trials have examined whether 
surgery is necessary after chemoradiation. In the Federation 
Francaise de Cancerologie Digestive (FFCD) 9102 trial, 
445 patients with clinically resectable T3-4N0-1M0 
SCC or adenocarcinoma of the esophagus received initial 
chemoradiation [64]. Patients initially received 2 cycles 
of 5-FU, cisplatin, and concurrent radiation (either 46 Gy 
at 2 Gy/day or split course 15 Gy weeks 1 and 3). The 
259 patients who had at least a partial response were then 
randomized to surgery versus additional chemoradiation 
which included 3 cycles of 5-FU, cisplatin, and concurrent 
radiation (either 20 Gy at 2 Gy/day or split course 15 Gy). 
There was no significant difference in 2-year survival (34% 
vs. 40%, p=0.56) or median survival (18 months vs. 19 
months) in patients who underwent surgery versus additional 
chemoradiation. These data suggest that for patients who 
initially respond to chemoradiation, they should complete 
chemoradiation rather than stop and undergo surgery. 
Using the Spitzer index, there was no difference in global 
quality of life however, a significantly greater decrease in 
quality of life was observed in the surgery arm during the 
postoperative period (7.52 vs. 8.45, p<0.01, respectively) 
[65]. A separate analysis revealed that compared with split 
course radiation, patients who received standard course 
radiation had improved 2-year local relapse free survival 
rates (77% vs. 57%, p=0.002) but no significant difference 
in overall survival (37% vs. 31%) [66].
The second trial, from the German Oesophageal Cancer 
Study Group, compared preoperative chemoradiation 
followed by surgery versus chemoradiation alone [67]. In 
this trial, 172 eligible patients < 70 years old with uT3-
4N0-1M0 SCC were randomized to preoperative therapy 
(3 cycles of 5-FU, leucovorin, etoposide, and cisplatin, 
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followed by concurrent etoposide, cisplatin, plus 40 Gy) 
followed by surgery versus chemoradiation alone (the same 
chemotherapy but the radiation dose was increased to 60-65 
Gy +/- brachytherapy). The pCR rate was 33%. Although 
there was a decrease in 2-year local failure (36% vs. 58%, 
p=0.003) there was no significant difference in 3-year 
survival (31% vs. 24%) for those who were randomized 
to preoperative chemoradiation followed by surgery vs. 
chemoradiation alone. 
Despite the above data, the current standard of care is 
to perform esophagectomy following chemoradiation in 
patients that can tolerate this approach. However, it is known 
that a subset of patients will have a complete response to 
chemoradiation. Further, it is known that patients with pCR 
have improved survival. Data from both Berger et al [68] 
and Rohatgi et al [69] suggest that patients who achieve a 
pCR had an improvement in survival compared to those 
who do not (5-year: 48% vs. 15%, and median: 133 months 
vs. 34 months, respectively). In these patients, surgical 
resection may not be necessary and has led to the concept 
of “selective” surgery after preoperative chemoradiation. 
Swisher and colleagues reported a retrospective analysis of 
patients who underwent a salvage compared with a planned 
esophagectomy [70]. The operative mortality was higher in 
those who underwent salvage vs. planned surgery (15% vs. 
6%) but there was no difference in survival (25%).   
  However, only 13 patients were identified who had 
salvage, limiting the broad interpretation of these findings. 
However, a recent phase II trial, RTOG 0246, prospectively 
examined the approach of preoperative paclitaxel/CDDP 
and 50.4 Gy followed by selective surgery in patients with 
either residual disease or recurrent disease in the absence of 
distant metastasis. In this trial of 43 patients with LAEC, 
21 patients required surgical resection after chemoradiation 
due to residual (17 patients) or recurrent (3 patients) disease 
[71]. This approach led to a one year overall survival of 
71%, lower than the predetermined survival rate (77.5%). 
Since all patients do not undergo surgery after neoadjuvant 
therapy, the use of a definitive does of radiation (50.4 Gy) 
rather than 41.4 Gy, is recommended. 
Conclusions 
The management of esophageal cancer continues to evolve. 
Approaches include both preoperative and non-operative 
approaches, based on resectability, histology and location. 
In patients with resectable disease, who are medically fit for 
this procedure, we recommend preoperative chemoradiation 
to 50.4 Gy. One possible exception to this recommendation 
is SCC of the cervical esophagus, for which definitive 
chemoradiation should be considered. Additionally, in non-
operative patients, definitive chemoradiation to 50.4 Gy is 
standard; however enrollment of these patients on dose-
escalation or other protocols is encouraged. Future directions 
include evaluation of tumor biomarkers of response to 
chemoradiation with a goal of possibly omitting surgery 
in favorable patients, while targeting non-responders for 
protocol based chemotherapy and radiosensitizers. 
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